936 related articles for article (PubMed ID: 27550399)
41. [Analysis of the Risk Factors Associated with Minor Bleeding in Patients with Venous Thromboembolism during Treatment with Direct Oral Anticoagulants].
Sunaga T; Shimizu T; Nakamura S; Takahashi N; Higashino M; Matsui M; Hozumi T; Ebato M; Suzuki H; Kogo M; Watanabe T; Sasaki T
Yakugaku Zasshi; 2019; 139(3):461-467. PubMed ID: 30828024
[TBL] [Abstract][Full Text] [Related]
42. Effects of direct oral anticoagulants on thromboelastographic parameters and fibrin clot properties in patients with venous thromboembolism.
Kopytek M; Zabczyk M; Natorska J; Malinowski KP; Undas A
J Physiol Pharmacol; 2020 Feb; 71(1):. PubMed ID: 32350148
[TBL] [Abstract][Full Text] [Related]
43. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
44. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review.
Gómez-Outes A; Suárez-Gea ML; Lecumberri R; Terleira-Fernández AI; Vargas-Castrillón E
Vasc Health Risk Manag; 2014; 10():627-39. PubMed ID: 25404858
[TBL] [Abstract][Full Text] [Related]
45. DOACs Versus VKAs in Older Adults Treated for Acute Venous Thromboembolism: Systematic Review and Meta-Analysis.
Chaudhary R; Pagali S; Garg J; Murad MH; Wysokinski WE; McBane RD
J Am Geriatr Soc; 2020 Sep; 68(9):2021-2026. PubMed ID: 32441334
[TBL] [Abstract][Full Text] [Related]
46. Pros and cons of new oral anticoagulants in the treatment of venous thromboembolism in patients with cancer.
Verso M; Agnelli G; Prandoni P
Intern Emerg Med; 2015 Sep; 10(6):651-6. PubMed ID: 25840679
[TBL] [Abstract][Full Text] [Related]
47. Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: a systematic review, pairwise and network meta-analysis.
Su X; Yan B; Wang L; Cheng H; Chen Y
BMJ Open; 2022 Feb; 12(2):e048619. PubMed ID: 35190410
[TBL] [Abstract][Full Text] [Related]
48. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
49. Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism in Japan.
Nakamura M; Yamada N; Ito M
J Atheroscler Thromb; 2017 Jun; 24(6):560-565. PubMed ID: 28392512
[TBL] [Abstract][Full Text] [Related]
50. Italian intersociety consensus on DOAC use in internal medicine.
Prisco D; Ageno W; Becattini C; D'Angelo A; Davì G; De Cristofaro R; Dentali F; Di Minno G; Falanga A; Gussoni G; Masotti L; Palareti G; Pignatelli P; Santi RM; Santilli F; Silingardi M; Tufano A; Violi F; ; ;
Intern Emerg Med; 2017 Apr; 12(3):387-406. PubMed ID: 28191610
[TBL] [Abstract][Full Text] [Related]
51. Editor's Choice - Severe Bleeding Risks of Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism: A Network Meta-Analysis of Randomised Controlled Trials.
Chen J; Lv M; Wu S; Jiang S; Xu W; Qian J; Chen M; Fang Z; Zeng Z; Zhang J
Eur J Vasc Endovasc Surg; 2022 Mar; 63(3):465-474. PubMed ID: 34973879
[TBL] [Abstract][Full Text] [Related]
52. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
[TBL] [Abstract][Full Text] [Related]
53. Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge.
Basto AN; Fewel NP; Vo K; Stock EM; Ta M
J Thromb Thrombolysis; 2018 Jan; 45(1):51-55. PubMed ID: 29086244
[TBL] [Abstract][Full Text] [Related]
54. Which patients with unprovoked venous thromboembolism should receive extended anticoagulation with direct oral anticoagulants? A systematic review, network meta-analysis, and decision analysis.
Djulbegovic M; Lee AI; Chen K
J Eval Clin Pract; 2020 Feb; 26(1):7-17. PubMed ID: 31190408
[TBL] [Abstract][Full Text] [Related]
55. Long-term benefits of preventing venous thromboembolic events.
Cohen AT
Curr Med Res Opin; 2012 Jun; 28(6):877-89. PubMed ID: 22533680
[TBL] [Abstract][Full Text] [Related]
56. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer.
Schulman S; Goldhaber SZ; Kearon C; Kakkar AK; Schellong S; Eriksson H; Hantel S; Feuring M; Kreuzer J
Thromb Haemost; 2015 Jul; 114(1):150-7. PubMed ID: 25739680
[TBL] [Abstract][Full Text] [Related]
57. Direct oral anticoagulants versus standard anticoagulation in children treated for acute venous thromboembolism.
Chen J; Bi G; Wu F; Qin X
Pediatr Res; 2023 May; 93(6):1491-1498. PubMed ID: 36071237
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis.
Dawwas GK; Brown J; Dietrich E; Park H
Lancet Haematol; 2019 Jan; 6(1):e20-e28. PubMed ID: 30558988
[TBL] [Abstract][Full Text] [Related]
59. Economic Evaluation of Direct Oral Anticoagulants Compared to Warfarin for Venous Thromboembolism in Thailand: A Cost-Utility Analysis.
Niyomsri S; Nimworapan M; Wongcharoen W; Dilokthornsakul P
Int J Environ Res Public Health; 2023 Feb; 20(4):. PubMed ID: 36833871
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of oral anticoagulants in extreme weights.
Chin-Hon J; Davenport L; Huang J; Akerman M; Hindenburg A
Thromb Res; 2023 Nov; 231():1-6. PubMed ID: 37738772
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
